DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: COPAXONE

Summary for Tradename: COPAXONE

Patents:10
Applicants:1
NDAs:1
Suppliers: see list1
2013 Sales:$3,697,182,000
drug
patent expirations by year for
 COPAXONE

Clinical Trials for: COPAXONE

A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.
Status: Completed Condition: Relapsing Remitting Multiple Sclerosis

Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis
Status: Completed Condition: Multiple Sclerosis

Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation
Status: Active, not recruiting Condition: Diabetic Retinopathy

Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline
Status: Completed Condition: Relapse Remitting Multiple Sclerosis

Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)
Status: Recruiting Condition: Rett Syndrome

Treatment of Multiple Sclerosis With Copaxone and Albuterol
Status: Completed Condition: Autoimmune Diseases; Multiple Sclerosis

Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI
Status: Active, not recruiting Condition: Multiple Sclerosis

A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.
Status: Completed Condition: Multiple Sclerosis

Efficacy and Safety of GTR in Comparison to Copaxone®
Status: Active, not recruiting Condition: Multiple Sclerosis

An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome
Status: Recruiting Condition: Rett Syndrome

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Usa
COPAXONE
glatiramer acetate
FOR SOLUTION;SUBCUTANEOUS020622Dec 20, 1996DISCNNo5,981,589<disabled><disabled>
Teva Pharms Usa
COPAXONE
glatiramer acetate
FOR SOLUTION;SUBCUTANEOUS020622Dec 20, 1996DISCNNo6,054,430<disabled><disabled>
Teva Pharms Usa
COPAXONE
glatiramer acetate
FOR SOLUTION;SUBCUTANEOUS020622Dec 20, 1996DISCNNo6,342,476<disabled><disabled>
Teva Pharms Usa
COPAXONE
glatiramer acetate
FOR SOLUTION;SUBCUTANEOUS020622Dec 20, 1996DISCNNo6,362,161<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc